Assenagon Asset Management’s Spero Therapeutics SPRO Stock Holding History

Assenagon Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.2K	Hold	18,636	–	–	﹤0.01%	1158
2026 Q1	$43.6K	Hold	18,636	–	–	﹤0.01%	1095
2025 Q4	$43.4K	Sell	18,636 -18,357	-50%	-$42.6K	﹤0.01%	1140
2025 Q3	$69.5K	Buy	+36,993	New	+$81.3K	﹤0.01%	1156
2022 Q3	–	Sell	-131,020	Closed	-$97K	–	1531
2022 Q2	$97K	Buy	131,020 +107,897	+467%	+$314K	﹤0.01%	1410
2022 Q1	$201K	Buy	+23,123	New	+$237K	﹤0.01%	1358
2021 Q2	–	Sell	-181,578	Closed	-$2.67M	–	1397
2021 Q1	$2.67M	Buy	181,578 +57,793	+47%	+$1.02M	0.01%	649
2020 Q4	$2.4M	Buy	+123,785	New	+$1.93M	0.01%	486

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Assenagon Asset Management's SPRO Position: Q2 2026 in Review

Assenagon Asset Management held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 18,636 shares worth $41.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Assenagon Asset Management first reported a position in SPRO in Q4 2020 and has held it in 8 quarters since. The position peaked at $2.67M in Q1 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Assenagon Asset Management held 18,636 shares of Spero Therapeutics worth $41.2K as of Q2 2026.
Assenagon Asset Management left its Spero Therapeutics share count unchanged in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1158 holding.
Assenagon Asset Management first reported a position in Spero Therapeutics in Q4 2020 and has held it in 8 quarters since.
Assenagon Asset Management's Spero Therapeutics position peaked at $2.67M in Q1 2021.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.